India’s pharma ascension: 20% of global generic drugs, 40% of US generic approvals. But 70% API import dependence on China defines the next decade.

Healthcare cyber crisis: 500+ ransomware attacks in 2024. Change Healthcare paid $22M ransom. Five board-level priorities hospital leadership must address.

Longevity economy: $27B invested since 2020. Altos Labs, Retro Biosciences, Calico shaping the category. ARPA-H commits $2.5B.

Value-based care crosses 50% Medicare Advantage penetration. Five forces rewriting healthcare business models — payers, providers, employers.

AI drug discovery: $50B in Big Pharma partnerships since 2022. Insilico, Recursion, Isomorphic compressing pharma timelines from decade to 18 months.

GLP-1 disruption beyond pharma: 12M Americans on Ozempic. Five industries — food, insurance, healthcare, consumer goods, telehealth — reshaped.

The era of easy D2C success on cheap social ads is over. Customer acquisition costs have soared, retention has disappointed, and legacy retailers have caught up. What’s actually working for D2C brands in 2026 — and what has stopped.

China Plus One has moved from hedging strategy to defining principle of global supply chain design. With US tariffs hitting Vietnam, Thailand, and Malaysia, companies face a more comprehensive challenge — building resilience across many geographies.

Carbon markets are now a $2 trillion infrastructure layer. Compliance markets are setting prices that affect corporate decisions; voluntary markets are recovering with stronger methodology. For carbon-exposed businesses, engagement is no longer optional.